Avodart (dutasteride) capsules 0.5 mg. №30

$81.00

Manufacturer: Poland

Purpose: Inhibits DHT production to treat enlarged prostate (BPH) symptoms.

SKU: MED56710 Category:

Description

Avodart (dutasteride) capsules 0.5 mg. №30

Ingredients

Active ingredient: Dutasteride 0.5 mg.
Other ingredients: (insert other ingredients here).

Dosage

Adult dosage: The recommended dose is one capsule (0.5 mg) daily with or without food.

Indications

Avodart (dutasteride) capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention, and decrease the risk of the need for BPH-related surgery.

Contraindications

Avodart (dutasteride) capsules are contraindicated in women and children. It should not be handled by pregnant women due to the potential risk to the male fetus.

Directions

Take Avodart (dutasteride) capsules exactly as prescribed by your healthcare provider. Swallow the capsules whole with a full glass of water. Do not chew or crush the capsules.

Scientific Evidence

Dutasteride, the active ingredient in Avodart, is a 5-alpha-reductase inhibitor that works by decreasing the production of dihydrotestosterone (DHT), a hormone that contributes to prostate growth. Clinical studies have shown that dutasteride effectively reduces prostate size, improves urinary symptoms, and reduces the risk of disease progression in men with BPH.

Additional Information

It may take several months of treatment with Avodart (dutasteride) to see the full benefits. Inform your healthcare provider about any other medications you are taking before starting Avodart to avoid potential drug interactions.

Pharmacological Effects: Dutasteride inhibits the conversion of testosterone to DHT, leading to a reduction in prostate volume and improvement in urinary symptoms in patients with BPH.

Clinical Trials: A randomized controlled trial published in the New England Journal of Medicine demonstrated that dutasteride significantly reduced the risk of acute urinary retention and the need for BPH-related surgery compared to placebo.